BioPartners Holdings AG Submits Its Novel Interferon beta-1a, Biferonex(R), To The EMEA

BAAR, Switzerland--(BUSINESS WIRE)--Biopartners Holdings AG today announced that it has submitted a marketing authorization application for Biferonex® (interferon beta-1a) to the EMEA. Biferonex represents a fully innovative, pH neutral and human serum albumin (HSA) free formulation providing an optimized interferon beta treatment solution for patients suffering from relapsing remitting multiple sclerosis (RRMS).